metformin has been researched along with Anemia in 16 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Anemia: A reduction in the number of circulating ERYTHROCYTES or in the quantity of HEMOGLOBIN.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This retrospective cohort study determines whether metformin monotherapy or combination therapies can decrease anemia risk in the progress of advanced chronic kidney disease for patients with type 2 diabetes mellitus." | 8.12 | Metformin and the Risk of Anemia of Advanced Chronic Kidney Disease in Patients With Type 2 Diabetes Mellitus. ( Fu, SL; Hsiung, CA; Jung, HK; Lai, JN; Liu, HY; Tsai, YT; Wu, CT, 2022) |
| "To evaluate the association between metformin use and anemia risk in type 2 diabetes, and the time-course for this, in a randomized controlled trial (RCT) and real-world population data." | 7.96 | Risk of Anemia With Metformin Use in Type 2 Diabetes: A MASTERMIND Study. ( Coleman, RL; Dennis, JM; Donnelly, LA; Hattersley, AT; Holman, RR; Pearson, ER; Sattar, N, 2020) |
| "Long-term use of metformin in DPPOS was associated with biochemical B12 deficiency and anemia." | 5.22 | Long-term Metformin Use and Vitamin B12 Deficiency in the Diabetes Prevention Program Outcomes Study. ( Aroda, VR; Bray, GA; Crandall, JP; Edelstein, SL; Goldberg, RB; Knowler, WC; Marcovina, SM; Orchard, TJ; Schade, DS; Temprosa, MG; White, NH, 2016) |
| "This retrospective cohort study determines whether metformin monotherapy or combination therapies can decrease anemia risk in the progress of advanced chronic kidney disease for patients with type 2 diabetes mellitus." | 4.12 | Metformin and the Risk of Anemia of Advanced Chronic Kidney Disease in Patients With Type 2 Diabetes Mellitus. ( Fu, SL; Hsiung, CA; Jung, HK; Lai, JN; Liu, HY; Tsai, YT; Wu, CT, 2022) |
| "To evaluate the association between metformin use and anemia risk in type 2 diabetes, and the time-course for this, in a randomized controlled trial (RCT) and real-world population data." | 3.96 | Risk of Anemia With Metformin Use in Type 2 Diabetes: A MASTERMIND Study. ( Coleman, RL; Dennis, JM; Donnelly, LA; Hattersley, AT; Holman, RR; Pearson, ER; Sattar, N, 2020) |
| "Nondiabetic patients with LAHNSCC were enrolled in the current study to receive escalating doses of metformin and CRT based on the modified toxicity probability interval design." | 2.94 | Phase 1 dose-finding study of metformin in combination with concurrent cisplatin and radiotherapy in patients with locally advanced head and neck squamous cell cancer. ( Desai, J; Desai, PB; Gulati, S; Gutkind, JS; Jandarov, R; Mierzwa, M; Molinolo, A; Morris, JC; Palackdharry, SM; Riaz, MK; Sadraei, NH; Takiar, V; Wise-Draper, TM; Zhu, Z, 2020) |
| "Metformin can cause serum vitamin B12 deficiency, but studies on the influence of its duration and dose are lacking." | 1.51 | Association between metformin dose and vitamin B12 deficiency in patients with type 2 diabetes. ( Ahn, CW; Fang, S; Kim, J; Lee, HS; Park, JS, 2019) |
| "During eight weeks all patients with type 2 diabetes visiting the diabetic outpatient clinic of the Isala Clinics in Zwolle were approached for participation." | 1.39 | Vitamin B12 deficiency and the lack of its consequences in type 2 diabetes patients using metformin. ( Bilo, HJ; de Groot-Kamphuis, DM; Groenier, KH; Houweling, ST; Kleefstra, N; van Dijk, PR, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (12.50) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 9 (56.25) | 24.3611 |
| 2020's | 5 (31.25) | 2.80 |
| Authors | Studies |
|---|---|
| Wu, CT | 1 |
| Tsai, YT | 1 |
| Jung, HK | 1 |
| Fu, SL | 1 |
| Hsiung, CA | 1 |
| Liu, HY | 1 |
| Lai, JN | 1 |
| Gulati, S | 1 |
| Desai, J | 1 |
| Palackdharry, SM | 1 |
| Morris, JC | 1 |
| Zhu, Z | 1 |
| Jandarov, R | 1 |
| Riaz, MK | 1 |
| Takiar, V | 1 |
| Mierzwa, M | 1 |
| Gutkind, JS | 1 |
| Molinolo, A | 1 |
| Desai, PB | 1 |
| Sadraei, NH | 1 |
| Wise-Draper, TM | 1 |
| Kim, J | 1 |
| Ahn, CW | 1 |
| Fang, S | 1 |
| Lee, HS | 1 |
| Park, JS | 1 |
| Donnelly, LA | 1 |
| Dennis, JM | 1 |
| Coleman, RL | 1 |
| Sattar, N | 1 |
| Hattersley, AT | 1 |
| Holman, RR | 1 |
| Pearson, ER | 1 |
| Attiya, N | 1 |
| Aung, TKK | 1 |
| Chuah, TY | 1 |
| Chua, MWJ | 1 |
| Yang, W | 1 |
| Cai, X | 1 |
| Wu, H | 1 |
| Ji, L | 1 |
| de Groot-Kamphuis, DM | 1 |
| van Dijk, PR | 1 |
| Groenier, KH | 1 |
| Houweling, ST | 1 |
| Bilo, HJ | 1 |
| Kleefstra, N | 1 |
| Weinrauch, LA | 1 |
| D'Elia, JA | 1 |
| Finn, P | 1 |
| Lewis, EF | 1 |
| Desai, AS | 1 |
| Claggett, BL | 1 |
| Cooper, ME | 1 |
| McGill, JB | 1 |
| Aroda, VR | 1 |
| Edelstein, SL | 1 |
| Goldberg, RB | 1 |
| Knowler, WC | 1 |
| Marcovina, SM | 1 |
| Orchard, TJ | 1 |
| Bray, GA | 1 |
| Schade, DS | 1 |
| Temprosa, MG | 1 |
| White, NH | 1 |
| Crandall, JP | 1 |
| Esteban Jiménez, O | 1 |
| González Rubio, F | 1 |
| Buñuel Granados, JM | 1 |
| Navarro Pemán, C | 1 |
| Hidalgo, SF | 1 |
| Prieto de Paula, JM | 1 |
| Salado Valdivieso, I | 1 |
| Trask, LE | 1 |
| Abbott, D | 1 |
| Lee, HK | 1 |
| Pierce, SA | 1 |
| Chung, AH | 1 |
| Black, KK | 1 |
| Marquié, G | 1 |
| Agid, R | 1 |
| Harris, EL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Diabetes Prevention Program Outcomes Study[NCT00038727] | Phase 3 | 2,779 participants (Actual) | Interventional | 2002-09-30 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Primary outcome for years 2002-2008 defined according to American Diabetes Association criteria (fasting plasma glucose level >= 126 mg/dL [7.0 mmol/L] or 2-hour plasma glucose >= 200 mg/dL [11.1 mmol/L], after a 75 gram oral glucose tolerance test (OGTT), and confirmed with a repeat test). (NCT00038727)
Timeframe: Outcomes were assessed from 1996-2008 (approximately 12 years including 6 years of DPP).
| Intervention | diabetes incidence (cases per 100 person (Number) |
|---|---|
| 1 Original Lifestyle | 5.3 |
| 2 Original Metformin | 6.4 |
| 3 Original Placebo | 7.8 |
All cause-mortality through clinic reports and National Death Index search (NCT00038727)
Timeframe: Outcomes were assessed throughout follow-up from 1996 to 2022. National Death Index search conducted in 2019 using early release data as of Dec 2018.
| Intervention | Participants (Count of Participants) |
|---|---|
| 1 Original Lifestyle | 158 |
| 2 Original Metformin | 152 |
| 3 Original Placebo | 143 |
Aggregate microvascular disease is defined as the average prevalence of 3 components: (1) retinopathy measured by photography (ETDRS of 20 or greater); (2) neuropathy detected by Semmes Weinstein 10 gram monofilament, and (3) nephropathy based on estimated glomerular filtration rate (eGFR by chronic kidney disease (CKD-Epi) equation ) (<45 ml/min, confirmed) and albumin-to-creatinine ratio in spot urine (> 30mg/gm, confirmed). (NCT00038727)
Timeframe: Outcomes were assessed from 2012-2013 (approximately 2 years).
| Intervention | average percentage of participants (Number) |
|---|---|
| 1 Original Lifestyle | 11.3 |
| 2 Original Metformin | 13 |
| 3 Original Placebo | 12.4 |
Measured using coronary artery calcification (CAC). (NCT00038727)
Timeframe: Outcomes were assessed from 2012-2013 (approximately 2 years).
| Intervention | CAC geometric mean in AU (Geometric Mean) | |
|---|---|---|
| Men | Women | |
| 1 Original Lifestyle | 70.1 | 6.0 |
| 2 Original Metformin | 40.2 | 6.1 |
| 3 Original Placebo | 63.7 | 5.3 |
1 review available for metformin and Anemia
| Article | Year |
|---|---|
Associations between metformin use and vitamin B
Topics: Anemia; Case-Control Studies; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Per | 2019 |
3 trials available for metformin and Anemia
| Article | Year |
|---|---|
Phase 1 dose-finding study of metformin in combination with concurrent cisplatin and radiotherapy in patients with locally advanced head and neck squamous cell cancer.
Topics: Acute Kidney Injury; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy | 2020 |
Strategies for glucose control in a study population with diabetes, renal disease and anemia (Treat study).
Topics: Aged; Anemia; Australia; Blood Glucose; Diabetes Mellitus, Type 2; Europe; Female; Humans; Hypoglyce | 2016 |
Long-term Metformin Use and Vitamin B12 Deficiency in the Diabetes Prevention Program Outcomes Study.
Topics: Adult; Aged; Anemia; Diabetes Mellitus, Type 2; Female; Homocysteine; Humans; Hypoglycemic Agents; M | 2016 |
12 other studies available for metformin and Anemia
| Article | Year |
|---|---|
Metformin and the Risk of Anemia of Advanced Chronic Kidney Disease in Patients With Type 2 Diabetes Mellitus.
Topics: Adult; Age Factors; Aged; Anemia; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Hemo | 2022 |
Association between metformin dose and vitamin B12 deficiency in patients with type 2 diabetes.
Topics: Age Factors; Aged; Alcohol Drinking; Anemia; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Dos | 2019 |
Risk of Anemia With Metformin Use in Type 2 Diabetes: A MASTERMIND Study.
Topics: Adult; Aged; Anemia; Datasets as Topic; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Huma | 2020 |
[Oral diagnosis of vitamin B12 deficiency due to long-term metformin treatment: a case report].
Topics: Aged; Anemia; Diabetes Mellitus; Diagnosis, Oral; Female; Glossitis; Humans; Hypoglycemic Agents; Me | 2020 |
More Than Meets the Eye: A Patient with Hand Swelling and Newly Diagnosed Diabetes Mellitus.
Topics: Aged; Amlodipine; Anemia; Antihypertensive Agents; Blood Sedimentation; C-Reactive Protein; Diabetes | 2021 |
Vitamin B12 deficiency and the lack of its consequences in type 2 diabetes patients using metformin.
Topics: Aged; Anemia; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Erythrocyte Indices; Female; Hemog | 2013 |
[Vitamin B12 deficiency secondary to metformin therapy].
Topics: Aged; Anemia; Diabetes Mellitus, Type 2; Drug Synergism; Female; Folic Acid; Humans; Hyperhomocystei | 2010 |
[Metformin and vitamin B12 deficiency].
Topics: Aged; Anemia; Female; Folic Acid; Humans; Hyperhomocysteinemia; Hypoglycemic Agents; Intestinal Abso | 2010 |
Low hemoglobin A(1c)--good diabetic control?
Topics: Anemia; Diabetes Mellitus, Type 2; Erythropoietin; Female; Glycated Hemoglobin; Hepatitis C; Humans; | 2012 |
Evaluation of vitamin B12 monitoring in a veteran population on long-term, high-dose metformin therapy.
Topics: Anemia; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Drug Monitoring; Humans; Hypoglycemic Agen | 2012 |
[Effects of antidiabetic biguanides on various types of lipid mobilization in the rabbit].
Topics: Adrenalectomy; Anemia; Animals; Bloodletting; Cholesterol; Ethyl Ethers; Fatty Acids; Fatty Acids, N | 1973 |
Adverse reactions to oral antidiabetic agents.
Topics: Acetohexamide; Acidosis; Administration, Oral; Anemia; Chlorpropamide; Drug Antagonism; Drug Synergi | 1971 |